Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Blueprint Medicines Co. (NASDAQ:BPMC) has earned a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $122.11.

A number of research analysts recently weighed in on the stock. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday, December 9th. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. UBS Group assumed coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. Finally, Wedbush reissued an “outperform” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Thursday, November 14th.

Insider Transactions at Blueprint Medicines

In related news, CEO Kate Haviland sold 2,353 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the completion of the transaction, the chief executive officer now owns 150,824 shares of the company’s stock, valued at approximately $14,569,598.40. The trade was a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40. Following the transaction, the chief operating officer now directly owns 71,657 shares of the company’s stock, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,260 shares of company stock worth $768,057 over the last quarter. Corporate insiders own 4.21% of the company’s stock.

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds have recently bought and sold shares of BPMC. CWM LLC grew its stake in Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 590 shares in the last quarter. SG Americas Securities LLC grew its stake in Blueprint Medicines by 82.8% in the 2nd quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock worth $2,337,000 after buying an additional 9,819 shares in the last quarter. Baader Bank Aktiengesellschaft grew its stake in Blueprint Medicines by 59.0% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 3,498 shares of the biotechnology company’s stock worth $371,000 after buying an additional 1,298 shares in the last quarter. Triad Wealth Partners LLC purchased a new position in Blueprint Medicines in the 2nd quarter worth approximately $27,000. Finally, Ellsworth Advisors LLC grew its stake in Blueprint Medicines by 6.8% in the 2nd quarter. Ellsworth Advisors LLC now owns 5,173 shares of the biotechnology company’s stock worth $558,000 after buying an additional 330 shares in the last quarter.

Blueprint Medicines Stock Up 0.7 %

Blueprint Medicines stock opened at $93.19 on Wednesday. Blueprint Medicines has a 1-year low of $72.24 and a 1-year high of $121.90. The firm has a market capitalization of $5.92 billion, a price-to-earnings ratio of -44.17 and a beta of 0.59. The firm’s fifty day moving average price is $92.03 and its two-hundred day moving average price is $97.47. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period last year, the firm earned ($2.20) earnings per share. The business’s quarterly revenue was up 126.5% compared to the same quarter last year. On average, equities research analysts predict that Blueprint Medicines will post -3.68 earnings per share for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.